CARA

Cara Therapeutics

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$32.7M

Burn Rate (Qtr)

$11.4M

Company Profile

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Korsuva IV (CR845 IV)

Pruritus CKD-HD

NDA Submission

Q4 2020

Oral Korsuva

Pruritus CKD 3-5

Phase 3 TBA

H2 2020

Oral Korsuva

Atopic Dermatitis

Phase 2 (Top-line results)

H1 2021

Oral Korsuva

Pruritus CLD

Phase 2 Topline Data

H1 2021

Recent Posts

See what the community is saying - click to see full post

CARA - Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020

CARA - Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patient

Educational video - Near-term dilution and follow-on offerings.

CARA DD Update

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon